Adaptive Biotechnologies Corp(ADPT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ADPT Adaptive Biotechnologies Corp

Closed 03-24 16:00:00 EDT

13.90

+0.24

+1.76%

盘后13.90

+0.000.00%

19:32 EDT

High13.95	Low13.41	Vol1.76M
Open13.55	D1 Closing13.66	Amplitude3.92%
Mkt Cap2.14B	Tradable Cap1.63B	Total Shares153.78M
T/O24.33M	T/O Rate1.50%	Tradable Shares117.37M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ADPT","market":"US","secType":"STK","nameCN":"Adaptive Biotechnologies Corp","latestPrice":13.9,"timestamp":1774382400000,"preClose":13.66,"halted":0,"volume":1762658,"hourTrading":{"tag":"盘后","latestPrice":13.9,"preClose":13.9,"latestTime":"19:32 EDT","volume":60294,"amount":838086.6,"timestamp":1774395145209,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.01756954612005858,"floatShares":117369033,"shares":153779418,"eps":-0.392158,"marketStatus":"Closed","change":0.24,"latestTime":"03-24 16:00:00 EDT","open":13.55,"high":13.945,"low":13.41,"amount":24330105.861323997,"amplitude":0.039165,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.392158,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1774425600000},"marketStatusCode":5,"adr":0,"listingDate":1561608000000,"exchange":"NASDAQ","adjPreClose":13.66,"preHourTrading":{"tag":"盘前","latestPrice":13.76,"preClose":13.66,"latestTime":"09:06 EDT","volume":61,"amount":830.8199999999999,"timestamp":1774357570202,"change":0.1,"changeRate":0.007321,"amplitude":0.027086},"postHourTrading":{"tag":"盘后","latestPrice":13.9,"preClose":13.9,"latestTime":"19:32 EDT","volume":60294,"amount":838086.6,"timestamp":1774395145209,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.067215,"impliedVol":0.8262,"impliedVolPercentile":0.4741},"requestUrl":"/m/hq/s/ADPT/tweets","defaultTab":"tweets","newsList":[{"id":"2622017526","title":"Adaptive Biotechnologies launches clonoSEQ MRD test for blood cancers","url":"https://stock-news.laohu8.com/highlight/detail?id=2622017526","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622017526?lang=en_us&edition=fundamental","pubTime":"2026-03-25 08:51","pubTimestamp":1774399877,"startTime":"0","endTime":"0","summary":"Adaptive highlighted clonoSEQ as a measurable residual disease test positioned to support treatment decisions across multiple blood cancer settings, with commercialization supported by FDA clearances in multiple myeloma, ALL, and CLL.Coverage expansion cited 300,000,000 covered lives, which the company framed as a driver of broader clinical adoption and recurring clinical testing volumes.Integration with Epic and Flatiron was presented as a route to embed ordering and results into clinical workflows, potentially supporting utilization growth.Trial adoption was cited at 19 studies using clonoSEQ as a primary endpoint, which may support biopharma services demand alongside clinical use.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adapt","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nNDL1XrKxT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","ADPT"],"gpt_icon":0},{"id":"2621261038","title":"Adaptive Biotechnologies President and COO Julie Rubinstein disposes of USD 765,393 in common shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2621261038","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621261038?lang=en_us&edition=fundamental","pubTime":"2026-03-24 07:19","pubTimestamp":1774307944,"startTime":"0","endTime":"0","summary":"Julie Rubinstein, President and COO of Adaptive Biotechnologies, reported transactions in common stock from March 19 to March 23, 2026.She exercised stock options for 44,166 shares at prices of USD 6.55 and USD 7.27.Rubinstein sold 57,180 shares at weighted average prices of USD 13.18, USD 13.37, and USD 13.83.Following the reported transactions, she beneficially owned 481,906 shares directly.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adaptive Biotechnologies Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 23, 2026, and is solely responsible for the information cont","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nNDL87tzsb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Adaptive Biotechnologies President and COO Julie Rubinstein disposes of USD 765,393 in common shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADPT","BK4121"],"gpt_icon":0},{"id":"2620275320","title":"Assessing Adaptive Biotechnologies (ADPT) Valuation After Strong Q4 Results And MRD Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2620275320","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620275320?lang=en_us&edition=fundamental","pubTime":"2026-03-20 03:10","pubTimestamp":1773947444,"startTime":"0","endTime":"0","summary":"Adaptive Biotechnologies (ADPT) is back on investor radar after fourth quarter results topped expectations, supported by its Minimal Residual Disease business and growing clonoSEQ adoption, while recent insider sales largely reflected tax related share transactions.\nSee our latest analysis for Adaptive Biotechnologies.\nAt a share price of US$13.28, Adaptive Biotechnologies has seen a 1 month share price return of a 17.21% decline and a 90 day share price return of a 19.52% decline. However,...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-adpt/adaptive-biotechnologies/news/assessing-adaptive-biotechnologies-adpt-valuation-after-stro","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-adpt/adaptive-biotechnologies/news/assessing-adaptive-biotechnologies-adpt-valuation-after-stro","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ADPT","BK4121"],"gpt_icon":0},{"id":"2620293149","title":"Adaptive Biotechnologies President and COO Julie Rubinstein reports USD 766,000 common share disposal","url":"https://stock-news.laohu8.com/highlight/detail?id=2620293149","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620293149?lang=en_us&edition=fundamental","pubTime":"2026-03-19 06:21","pubTimestamp":1773872503,"startTime":"0","endTime":"0","summary":"Julie Rubinstein, President and COO of Adaptive Biotechnologies, reported transactions in the company’s common stock dated March 16, 2026. She acquired 14,722 shares at USD 6.55 through an option exercise and sold 19,060 shares at an average price of USD 13.41. Julie Rubinstein reported additional option exercises of 14,722 shares on March 17, 2026 and March 18, 2026. She also sold 19,060 shares on March 17, 2026 at an average price of USD 13.4 and on March 18, 2026 at an average price of USD 13.18. Following the reported transactions, she beneficially owned 494,920 shares of common stock.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adaptive Biotechnologies Corporation published the original content used to generate this news brief ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL9CpS9j:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Adaptive Biotechnologies President and COO Julie Rubinstein reports USD 766,000 common share disposal","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADPT","BK4121"],"gpt_icon":0},{"id":"2620495192","title":"Adaptive Biotechnologies (ADPT) Is Down 11.9% After MRD-Led Earnings Beat And Tax-Driven Insider Sales - Has The Bull Case Changed?","url":"https://stock-news.laohu8.com/highlight/detail?id=2620495192","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620495192?lang=en_us&edition=fundamental","pubTime":"2026-03-17 00:17","pubTimestamp":1773677866,"startTime":"0","endTime":"0","summary":"In March 2026, Adaptive Biotechnologies reported fourth-quarter 2025 results that beat analyst expectations, with revenue growth led by its Minimal Residual Disease (MRD) business, while several senior executives sold shares largely to cover tax obligations linked to vested equity awards. \nThis combination of stronger MRD performance and insider sales tied mainly to tax withholding offers insight into how operational momentum and routine executive transactions can coexist without necessarily...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-adpt/adaptive-biotechnologies/news/adaptive-biotechnologies-adpt-is-down-119-after-mrd-led-earn","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-adpt/adaptive-biotechnologies/news/adaptive-biotechnologies-adpt-is-down-119-after-mrd-led-earn","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ADPT"],"gpt_icon":0},{"id":"2619941141","title":"Adaptive Biotechnologies Chief People Officer Francis Lo Disposes of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2619941141","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619941141?lang=en_us&edition=fundamental","pubTime":"2026-03-14 09:02","pubTimestamp":1773450170,"startTime":"0","endTime":"0","summary":"Francis Lo, Chief People Officer of Adaptive Biotechnologies Corporation, reported a disposal of common shares. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adaptive Biotechnologies Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 13, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260314:nNDL8qSk8Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Adaptive Biotechnologies Chief People Officer Francis Lo Disposes of Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","ADPT"],"gpt_icon":0},{"id":"2617503582","title":"Adaptive Biotechnologies Director Michelle Renee Griffin Disposes of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2617503582","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617503582?lang=en_us&edition=fundamental","pubTime":"2026-03-06 09:05","pubTimestamp":1772759153,"startTime":"0","endTime":"0","summary":"Michelle Renee Griffin, a director of Adaptive Biotechnologies Corporation, reported a disposal of common shares. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adaptive Biotechnologies Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 05, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260306:nNDL2cg4fR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Adaptive Biotechnologies Director Michelle Renee Griffin Disposes of Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","ADPT"],"gpt_icon":0},{"id":"2617595889","title":"Adaptive Biotechnologies Chief Scientific Officer Harlan S. Robins Disposes of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2617595889","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617595889?lang=en_us&edition=fundamental","pubTime":"2026-03-05 08:59","pubTimestamp":1772672349,"startTime":"0","endTime":"0","summary":"Harlan S. Robins, Chief Scientific Officer of Adaptive Biotechnologies Corporation, reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adaptive Biotechnologies Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 04, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260305:nNDL9PSs1k:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Adaptive Biotechnologies Chief Scientific Officer Harlan S. Robins Disposes of Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","ADPT"],"gpt_icon":0},{"id":"2616306390","title":"Adaptive Biotechnologies CEO and Chairman Chad M. Robins Disposes of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2616306390","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616306390?lang=en_us&edition=fundamental","pubTime":"2026-03-04 08:52","pubTimestamp":1772585523,"startTime":"0","endTime":"0","summary":"Chad M. Robins, CEO and Chairman of Adaptive Biotechnologies Corporation, reported a disposal of the company’s common shares. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adaptive Biotechnologies Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 03, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260304:nNDL5dK73j:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Adaptive Biotechnologies CEO and Chairman Chad M. Robins Disposes of Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","ADPT"],"gpt_icon":0},{"id":"2614007124","title":"Adaptive Biotech FY 2025 clonoSEQ test volume hits 105,587 (+39%)","url":"https://stock-news.laohu8.com/highlight/detail?id=2614007124","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614007124?lang=en_us&edition=fundamental","pubTime":"2026-02-27 05:48","pubTimestamp":1772142480,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adaptive Biotechnologies Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 26, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nNDL81NWZD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADPT","BK4121"],"gpt_icon":0},{"id":"2614402264","title":"Does Post‑Earnings Analyst Optimism Around clonoSEQ Adoption Change The Bull Case For Adaptive (ADPT)?","url":"https://stock-news.laohu8.com/highlight/detail?id=2614402264","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614402264?lang=en_us&edition=fundamental","pubTime":"2026-02-27 01:36","pubTimestamp":1772127363,"startTime":"0","endTime":"0","summary":"In recent days, Adaptive Biotechnologies received supportive research updates from TD Cowen, BTIG, and JPMorgan following the company’s strong Q4 results and improved outlook. \nAnalysts emphasized growing community adoption of its clonoSEQ minimal residual disease testing and progress on new indications, underscoring Adaptive’s position within specialty laboratory diagnostics.\nNext, we’ll examine how this post‑earnings analyst optimism, particularly around clonoSEQ’s community adoption, may...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-adpt/adaptive-biotechnologies/news/does-postearnings-analyst-optimism-around-clonoseq-adoption","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-adpt/adaptive-biotechnologies/news/does-postearnings-analyst-optimism-around-clonoseq-adoption","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["POST","ADPT"],"gpt_icon":0},{"id":"2613564987","title":"A Look At Adaptive Biotechnologies (ADPT) Valuation After Analyst Upgrades On Strong Q4 Earnings","url":"https://stock-news.laohu8.com/highlight/detail?id=2613564987","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613564987?lang=en_us&edition=fundamental","pubTime":"2026-02-24 07:26","pubTimestamp":1771889202,"startTime":"0","endTime":"0","summary":"What triggered the latest focus on Adaptive Biotechnologies?\nAdaptive Biotechnologies (ADPT) drew fresh investor attention after several analyst firms raised their outlook following what they described as strong Q4 earnings, citing multiple business drivers across its core testing and MRD-focused offerings.\nSee our latest analysis for Adaptive Biotechnologies.\nAt a share price of US$15.39, Adaptive Biotechnologies has recently seen pressure, with a 30 day share price return of 17.04% and a 90...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-adpt/adaptive-biotechnologies/news/a-look-at-adaptive-biotechnologies-adpt-valuation-after-anal","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-adpt/adaptive-biotechnologies/news/a-look-at-adaptive-biotechnologies-adpt-valuation-after-anal","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ADPT"],"gpt_icon":0},{"id":"2612452502","title":"How Strong 2025 Results and MRD-Focused 2026 Guidance At Adaptive Biotechnologies (ADPT) Has Changed Its Investment Story","url":"https://stock-news.laohu8.com/highlight/detail?id=2612452502","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612452502?lang=en_us&edition=fundamental","pubTime":"2026-02-17 19:25","pubTimestamp":1771327528,"startTime":"0","endTime":"0","summary":"In early February 2026, Adaptive Biotechnologies reported full-year 2025 results showing sales of US$276.98 million versus US$178.96 million a year earlier, and a net loss of US$59.5 million versus US$159.49 million, with basic loss per share from continuing operations improving to US$0.39 from US$1.08.\nOn the same day, the company issued 2026 guidance for its measurable residual disease (MRD) business, projecting full-year revenue between US$255 million and US$265 million while withholding...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-adpt/adaptive-biotechnologies/news/how-strong-2025-results-and-mrd-focused-2026-guidance-at-ada","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-adpt/adaptive-biotechnologies/news/how-strong-2025-results-and-mrd-focused-2026-guidance-at-ada","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4121","MRD.AU","BK7095","ADPT"],"gpt_icon":0},{"id":"2610646171","title":"Analysts Offer Insights on Healthcare Companies: Adaptive Biotechnologies (ADPT) and Medpace Holdings (MEDP)","url":"https://stock-news.laohu8.com/highlight/detail?id=2610646171","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610646171?lang=en_us&edition=fundamental","pubTime":"2026-02-10 18:20","pubTimestamp":1770718857,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Adaptive Biotechnologies (ADPT – Research Report) ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-adaptive-biotechnologies-adpt-and-medpace-holdings-medp-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-adaptive-biotechnologies-adpt-and-medpace-holdings-medp-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HCSG","MEDP","BK4581","BK4137","XBI","LU0128526141.USD","LU2065171311.SGD","LU0029874061.USD","LU2065170008.USD","LU2065171402.SGD","BK4588","LU2065169927.USD","BK4121","BK4585","XLV","ADPT","LABU"],"gpt_icon":0},{"id":"2609803528","title":"Adaptive Biotechnologies (ADPT) Q4 Loss Narrows Yet Premium Valuation Tests Bullish Narratives","url":"https://stock-news.laohu8.com/highlight/detail?id=2609803528","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609803528?lang=en_us&edition=fundamental","pubTime":"2026-02-07 19:10","pubTimestamp":1770462614,"startTime":"0","endTime":"0","summary":"Adaptive Biotechnologies (ADPT) closed out FY 2025 with Q4 revenue of US$71.7 million and a basic EPS loss of US$0.09, alongside net income excluding extra items of a US$13.6 million loss. This provides a clear snapshot of where the business stands after a volatile year. The company reported revenue of US$47.5 million in Q4 2024 and US$71.7 million in Q4 2025, while basic EPS moved from a loss of US$0.23 to a loss of US$0.09 over the same period. This places the focus on how far these revenue...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-adpt/adaptive-biotechnologies/news/adaptive-biotechnologies-adpt-q4-loss-narrows-yet-premium-va","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-adpt/adaptive-biotechnologies/news/adaptive-biotechnologies-adpt-q4-loss-narrows-yet-premium-va","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4112","ADPT","BK4121"],"gpt_icon":0},{"id":"2609510978","title":"Adaptive Biotechnologies CFO Kyle Piskel Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2609510978","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609510978?lang=en_us&edition=fundamental","pubTime":"2026-02-07 08:30","pubTimestamp":1770424247,"startTime":"0","endTime":"0","summary":"Kyle Piskel, Chief Financial Officer of Adaptive Biotechnologies Corporation, reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adaptive Biotechnologies Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 06, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260207:nNDL8HbLFV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Adaptive Biotechnologies CFO Kyle Piskel Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADPT","BK4121"],"gpt_icon":0},{"id":"1101204406","title":"Stock Track | Adaptive Biotechnologies Plummets 6.31% Intraday Following Analyst Insights","url":"https://stock-news.laohu8.com/highlight/detail?id=1101204406","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1101204406?lang=en_us&edition=fundamental","pubTime":"2026-02-07 00:24","pubTimestamp":1770395085,"startTime":"0","endTime":"0","summary":"Adaptive Biotechnologies Corp's stock plummeted 6.31% during intraday trading on Friday, reflecting a sharp decline in investor sentiment.The movement appears to be driven by analyst commentary on...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["ADPT"],"gpt_icon":0},{"id":"1191362368","title":"Stock Track | Adaptive Biotechnologies Soars 8.20% Intraday on Analyst Price Target Upgrades","url":"https://stock-news.laohu8.com/highlight/detail?id=1191362368","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1191362368?lang=en_us&edition=fundamental","pubTime":"2026-02-06 22:37","pubTimestamp":1770388656,"startTime":"0","endTime":"0","summary":"Adaptive Biotechnologies Corp (ADPT) experienced a significant surge of 8.20% during intraday trading on Friday, driven by positive analyst actions.JPMorgan analyst Sebastian Sandler raised the...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["ADPT"],"gpt_icon":0},{"id":"2609594463","title":"Analysts Are Bullish on These Healthcare Stocks: Adaptive Biotechnologies (ADPT), Opus Genetics (IRD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2609594463","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609594463?lang=en_us&edition=fundamental","pubTime":"2026-02-06 22:21","pubTimestamp":1770387677,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Adaptive Biotechnologies (ADPT – Research Report) an...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-adaptive-biotechnologies-adpt-opus-genetics-ird-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-adaptive-biotechnologies-adpt-opus-genetics-ird-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4112","LU0128526141.USD","BK4137","ADPT","IRD","BK4588","BK4007","LABU","XBI","BK4139","BK4581","LU0029874061.USD","BK4585","BK4121"],"gpt_icon":0},{"id":"2609196593","title":"Adaptive Biotechnologies price target raised to $22 from $21 at BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2609196593","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609196593?lang=en_us&edition=fundamental","pubTime":"2026-02-06 20:36","pubTimestamp":1770381408,"startTime":"0","endTime":"0","summary":"BTIG raised the firm’s price target on Adaptive Biotechnologies (ADPT) to $22 from $21 and keeps a Buy rating on the shares after its Q4 results. T...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/adaptive-biotechnologies-price-target-raised-to-22-from-21-at-btig-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/adaptive-biotechnologies-price-target-raised-to-22-from-21-at-btig-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4121","ADPT"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.adaptivebiotech.com","stockEarnings":[{"period":"1week","weight":0.0255},{"period":"1month","weight":-0.1013},{"period":"3month","weight":-0.1845},{"period":"6month","weight":0.0655},{"period":"1year","weight":0.6262},{"period":"ytd","weight":-0.1589}],"compareEarnings":[{"period":"1week","weight":-0.0204},{"period":"1month","weight":-0.0494},{"period":"3month","weight":-0.0474},{"period":"6month","weight":-0.0087},{"period":"1year","weight":0.1621},{"period":"ytd","weight":-0.0389}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":-0.006662},{"month":2,"riseRate":0.428571,"avgChangeRate":-0.034164},{"month":3,"riseRate":0.142857,"avgChangeRate":-0.110264},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.10078},{"month":5,"riseRate":0.5,"avgChangeRate":0.108472},{"month":6,"riseRate":0.833333,"avgChangeRate":0.100403},{"month":7,"riseRate":0.428571,"avgChangeRate":-0.001043},{"month":8,"riseRate":0.571429,"avgChangeRate":0.074393},{"month":9,"riseRate":0.428571,"avgChangeRate":-0.065733},{"month":10,"riseRate":0.285714,"avgChangeRate":-0.030408},{"month":11,"riseRate":0.714286,"avgChangeRate":0.049327},{"month":12,"riseRate":0.714286,"avgChangeRate":0.032336}],"exchange":"NASDAQ","name":"Adaptive Biotechnologies Corp","nameEN":"Adaptive Biotechnologies Corp"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Adaptive Biotechnologies Corp(ADPT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Adaptive Biotechnologies Corp(ADPT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Adaptive Biotechnologies Corp,ADPT,Adaptive Biotechnologies Corp股票,Adaptive Biotechnologies Corp股票老虎,Adaptive Biotechnologies Corp股票老虎国际,Adaptive Biotechnologies Corp行情,Adaptive Biotechnologies Corp股票行情,Adaptive Biotechnologies Corp股价,Adaptive Biotechnologies Corp股市,Adaptive Biotechnologies Corp股票价格,Adaptive Biotechnologies Corp股票交易,Adaptive Biotechnologies Corp股票购买,Adaptive Biotechnologies Corp股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Adaptive Biotechnologies Corp(ADPT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Adaptive Biotechnologies Corp(ADPT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}